Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.9K citations

Medicine, Oncology, Radiation Oncology +15

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial

Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology · 2017 · 1.3K citations

Medicine, Oncology, Urology +17

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez, Chad Tang, Jianjun Zhang et al. · Journal of Clinical Oncology · 2019 · 1.3K citations · Full text

Medicine, Oncology, Surgery +15

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Urology +17